Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia

Blood transfusion therapy for β‐thalassemia major and hemoglobin E β‐thalassemia: Adequacy, trends, and determinants in Sri Lanka

(2019) Sachith Mettananda et al.   PEDIATRIC BLOOD & CANCER

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?

(2018) Maria Domenica Cappellini et al.   BLOOD REVIEWS

Phenotypic and molecular characterization of a serum-free miniature erythroid differentiation system suitable for high-throughput screening and single-cell assays

(2018) Sachith Mettananda et al.   EXPERIMENTAL HEMATOLOGY

Interaction of Transfusion and Iron Chelation in Thalassemias

(2018) John B. Porter et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Molecular Basis and Genetic Modifiers of Thalassemia

(2018) Sachith Mettananda et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Thalassaemia

(2018) Ali T Taher et al.   LANCET

Anaemia among females in child-bearing age: Relative contributions, effects and interactions of α- and β-thalassaemia

(2018) Sachith Mettananda et al.   PLoS One

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia

(2017) Sachith Mettananda et al.   Nature Communications

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

(2017) Priscila H. Goncalves et al.   Oncotarget

Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia

(2016) Sachith Mettananda et al.   HAEMATOLOGICA

Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia

(2016) Sachith Mettananda et al.   HAEMATOLOGICA

Understanding α-globin gene regulation and implications for the treatment of β-thalassemia

(2015) Sachith Mettananda et al.   Annals of the New York Academy of Sciences

 -Globin as a molecular target in the treatment of  -thalassemia

(2015) S. Mettananda et al.   BLOOD

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea

(2015) M. M. Okam et al.   BLOOD

BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis

(2015) Matthew C. Canver et al.   NATURE

Anemia: progress in molecular mechanisms and therapies

(2015) Vijay G Sankaran et al.   NATURE MEDICINE

Targeting histone lysine demethylases — Progress, challenges, and the future

(2014) Cyrille C. Thinnes et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Modulation of gamma globin genes expression by histone deacetylase inhibitors: anin vitrostudy

(2014) Luisa Ronzoni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epigenetic reprogramming induces the expansion of cord blood stem cells

(2014) Pratima Chaurasia et al.   JOURNAL OF CLINICAL INVESTIGATION

Fetal Globin Gene Repressors as Drug Targets for Molecular Therapies To Treat the  -Globinopathies

(2014) M. Suzuki et al.   MOLECULAR AND CELLULAR BIOLOGY

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor

(2013) Marian Iwamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Switch from Fetal to Adult Hemoglobin

(2013) V. G. Sankaran et al.   Cold Spring Harbor Perspectives in Medicine

Reawakening fetal hemoglobin: prospects for new therapies for the  -globin disorders

(2012) D. E. Bauer et al.   BLOOD

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia

(2012) Swee Lay Thein   BLOOD REVIEWS

The challenge of haemoglobinopathies in resource-poor countries

(2011) David J. Weatherall   BRITISH JOURNAL OF HAEMATOLOGY

Thalassaemia

(2011) Douglas R Higgs et al.   LANCET

The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice

(2010) R. P. Hebbel et al.   BLOOD

The inherited diseases of hemoglobin are an emerging global health burden

(2010) D. J. Weatherall   BLOOD

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

(2010) James E. Bradner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases⊥

(2008) Nathan R. Rose et al.   JOURNAL OF MEDICINAL CHEMISTRY